10 cheap pharma stocks to explore as pandemic weakens

Summary

• OPKO Health, Inc. (Nasdaq: OPK) has a market capitalization of US$2.5 billion.
  
  
• Endo International plc (Nasdaq: ENDP) reported revenue of US$717.9 million in Q1, 2021.

• Antares Pharma, Inc. (Nasdaq: ATRS) reported gross profit of US$25.64 million in Q1, 2021.

Pharma stocks are companies that develop and market drugs for various diseases. These companies are always in demand as healthcare is an integral part of human lives.

Here we explore 10 pharmaceutical stocks that are less than US$5 apiece.

Source: Pixabay.

OPKO Health, Inc (Nasdaq: OPK)

OPKO Health Inc, a healthcare company, runs pharmaceutical operations and diagnostic laboratories in Chile, Mexico, Ireland, and Spain. The market capitalization of OPK is US$2.5 billion.

The stock of OPK traded at US$3.665 at 1.43 pm ET on July 23, a decrease by 0.41 percent over the closing price of July 22. The stock value of OPK went down by 7.49 percent YTD.

The total revenue of OPK for Q1, 2021 was US$545.2 million as compared to US$211.5 million for Q1, 2020. The gross profit for Q1, 2021 was US$181.7, and for Q1, 202 was US$71.2. Operating income for this quarter was US$38.4 million and losses of US$40.8 for Q1, 2020.

Also read: Johnson & Johnson (JNJ) posts strong Q2 results, lifts 2021 outlook

Endo International plc (Nasdaq: ENDP)

Endo International Plc is a genetic and branded pharmaceutical company. The stock of ENDP traded at US$4.94 at 2 pm ET on July 23, a rise of 1.02 percent over the closing price of July 22. The stock value of ENDP went down by 31.27 percent YTD.

The market capitalization of this pharmaceutical company is US$1.1 billion. The P/E ratio is 12.34, and Earnings per share (EPS) are US$0.40.

The company could earn revenue of US$717.9 million in Q1, 2021, a fall from US$820.4 million in Q1, 2020. Operating income for this quarter was US$182.7 million as compared to US$148.3 million YoY.

Amarin Corporation plc (Nasdaq: AMRN)

Amarin Corporation plc, a biopharmaceutical company based at Ireland, develops and sells medicines and treatment for cardiovascular diseases.

The stock of AMRN traded at US$.045 at 2.09 pm ET on July 23, a fall by 1.82 percent over the closing price of July 22. The stock value of AMRN went down by 16.97 percent YTD. The market capitalization of AMRN is US$1.6 billion.

The total revenue of this biopharmaceutical company for Q1, 2021 was US$142.2 million. And the company recorded a gross profit of US$113.8 in this quarter. 

Antares Pharma, Inc. (Nasdaq: ATRS)

Antares Pharma, Inc, a pharmaceutical company, develops and sells self-administered medicines and technologies like auto-injectors.

The stock of the ATRS traded at US$4.37 at 2.17 pm ET on July 23, a rise by 69 percent over the closing price of July 22. The stock value of this US-based company increased by 9.03 percent YTD.

ATRS could earn revenue of US$42.08 million in Q1, 2021 as compared to US$33.08 million in Q1, 2020. Gross profit for this quarter was US$25.64 million.

Source: Pixabay. 

Verastem, Inc.( Nasdaq: VSTM)

Verastem, Inc., a Biopharmaceutical Company, develops and sells medicines for cancer.

The stock of VSTM traded at US$3.385 at 2.28 pm ET on July 23, down by 2.87 percent over the closing price of July 22. The stock value of the Boston-based company swelled by 58.69 percent YTD. The market capitalization of the VSTM is US$582 million.

The company that launched its IPO in 2011 reported total revenue of US$1.01 million in Q1, 2021, down from US$5.06 percent. Gross profit also went down from US$4.56 million of Q1, 2020 to US$1.01 million Q1 of this year. 

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)

Lexicon Pharmaceuticals, Inc focuses on the development and commercialization of treatment for neuropathic pain.

The stock of LXRX traded at US$3.43 at 2.43 pm ET, a fall by 3.38 percent over the closing price of July 22. The company that launched its IPO in 2000 has a market capitalization of US$497 million. And its stock value soared by 0.88 percent YTD. LXRX’s EPS was US$-0.13 and the forward P/E one year -15.43. The beta is 1.48.

Also read: 8 healthcare stocks to explore in July

Geron Corporation (Nasdaq: GERN)

Geron Corporation, a clinical biopharmaceutical company, develops medication for malignancies.

The stock of GERN traded at US$1.315 at 2.52 pm ET on July 23, a rise of 1.94 percent over the closing price of July 22. The stock value of this company fell by 16.98 percent YTD. The market capitalization of GERN is US$420 million. The US-based company reported total revenue of US$14,000 in Q1, 2021.

TherapeuticsMD, Inc (Nasdaq: TXMD)

TherapeuticsMD, Inc, a healthcare company for women, creates and sells products related to hormone therapy connected with menopause.

The stock of TXMD traded at US$1.055 at 3.05 pm ET on July 23, a fall of 0.94 percent over the closing price of July 22. The stock value of TXMD fell by 13.22 percent YTD. The publically traded company since 2001 has a market capitalization of US$416 million.

The forward P/E 1-year is -2.65, and the beta is 1.92. EPS is US$-0.57. Its share volume is 2,223,513. TXMD’s revenue for the first quarter of 2021 was US$19.89 million as compared to US$12.25 million YoY. The gross profit of the company for this quarter was US$15.18 million, up from US$9.54 million in Q1, 2020.

Orchard Therapeutics plc (Nasdaq: ORTX)

Orchard Therapeutics plc, a biopharmaceutical company, manufactures and commercializes cell and gene therapies for various diseases.

The stock of ORTX traded at US$3.065 at 3.14 pm ET on July 23 over the closing price of July 22. The stock value fell by 28.76 percent YTD. The market capitalization of ORTX is US$378 million. And EPS is US$-1.33. The UK-based multinational company has a share volume of 448,599.

BioDelivery Sciences International, Inc (Nasdaq: BDSI)

BioDelivery Sciences International, Inc, a pharmaceutical company, develops and commercializes therapies connected with pain and addiction.

The stock of the BDSI traded at US$3.66 at 3.16 pm ET on July 23, a fall by 0.81 percent over the closing price of July 22. The stock value of BDSI fell by 13.33 percent. The market capitalization of this US-based pharma company is US$359 million. The P/E ratio is 14.59, and EPS is US$0.25.

The total revenue of BDSI for the first quarter of this year was US$41.02 million, up from US$38.28 million YoY.

Please note: The above constitutes a preliminary view, and any interest in stocks/cryptocurrencies should be evaluated further from an investment point of view.